CoronaVac®

BIOLOGICAL3 trials

Sponsors

AIM Vaccine Co., Ltd., Pontificia Universidad Catolica de Chile, Argorna Pharmaceuticals Co., LTD

Conditions

COVID-19SARS-CoV-2Vaccines

Phase 1

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

CompletedNCT05897190

Argorna Pharmaceuticals Co., LTDSARS-CoV-2

Start: 2022-05-16End: 2023-05-12Updated: 2024-03-25

Phase 2

Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile

CompletedNCT05593042

Pontificia Universidad Catolica de ChileCOVID-19, Vaccines

Start: 2022-11-28End: 2023-10-26Updated: 2024-02-07

Phase 3

Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad

AIM Vaccine Co., Ltd.SARS-CoV-2

Start: 2023-04-30End: 2024-10-31Target: 1100Updated: 2023-02-02

Related Papers

Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months

Scientific Reports2026-03-25

A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity.

2025-12-15